The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Renova Therapeutics’ lead product candidate, RT-100 AC6 gene transfer (Ad5.hAC6), for the treatment of heart failure with reduced ejection fraction (HFrEF).   “We’re pleased to work closely with the FDA to advance rapidly the development of RT-100 to treat heart failure patients,” said Dr. Jack W. Reich, chief executive officer and co-founder of Renova Therapeutics. “Despite some me...